Company / Operating Income
Decoy Therapeutics Inc. Operating Income History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$12.8M
FY2022
5-year range
-$39.9M / -$1.7M
FY2018-FY2022
Trend
-64.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 7 years, ranging from -$40M in FY2018 to -$2M in FY2019.
Based on SEC 10-K filings.
-$13M in FY2022.
Declined from -$8M to -$13M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating income decreased 64.6% year-over-year.
- Peak operating income was recorded in FY2019.
- Lowest operating income in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$12.8M | -64.6% |
| FY2021 | -$7.8M | +5.8% |
| FY2020 | -$8.3M | -390.6% |
| FY2019 | -$1.7M | +95.8% |
| FY2018 | -$39.9M | -36.5% |
| FY2017 | -$29.2M | -263.8% |
| FY2016 | -$8.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026